LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 10

Search options

  1. Article ; Online: Nanoparticle-Mediated Hyperthermia and Cytotoxicity Mechanisms in Cancer

    Vanessa-Meletia Bala / Dimitra Ioanna Lampropoulou / Stamatiki Grammatikaki / Vassilios Kouloulias / Nefeli Lagopati / Gerasimos Aravantinos / Maria Gazouli

    International Journal of Molecular Sciences, Vol 25, Iss 1, p

    2023  Volume 296

    Abstract: Hyperthermia has the potential to damage cancerous tissue by increasing the body temperature. However, targeting cancer cells whilst protecting the surrounding tissues is often challenging, especially when implemented in clinical practice. In this ... ...

    Abstract Hyperthermia has the potential to damage cancerous tissue by increasing the body temperature. However, targeting cancer cells whilst protecting the surrounding tissues is often challenging, especially when implemented in clinical practice. In this direction, there are data showing that the combination of nanotechnology and hyperthermia offers more successful penetration of nanoparticles in the tumor environment, thus allowing targeted hyperthermia in the region of interest. At the same time, unlike radiotherapy, the use of non-ionizing radiation makes hyperthermia an attractive therapeutic option. This review summarizes the existing literature regarding the use of hyperthermia and nanoparticles in cancer, with a focus on nanoparticle-induced cytotoxicity mechanisms.
    Keywords cancer ; hyperthermia ; nanoparticles ; cytotoxicity mechanisms ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Language English
    Publishing date 2023-12-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Encapsulated papillary carcinoma of the breast: An overview.

    George, Kyrgias / Anna, Zygogianni / Evanthia, Kostopoulou / Vassilios, Kouloulias

    Journal of cancer research and therapeutics

    2013  Volume 9, Issue 4, Page(s) 564–570

    Abstract: Any papillary growth of the breast presents both a diagnostic and a therapeutic challenge: For each one of them a diagnosis of whether they are malignant or benign in nature is required as well as appropriate staging and suitable treatment. In the ... ...

    Abstract Any papillary growth of the breast presents both a diagnostic and a therapeutic challenge: For each one of them a diagnosis of whether they are malignant or benign in nature is required as well as appropriate staging and suitable treatment. In the international literature, we find a considerable amount of different terms being used for papillary breast growths. As a result, pathological and clinical evaluation is somewhat problematic. Encapsulated papillary carcinoma (EPC) is an interesting subgroup of breast papillary tumours. Because of its rarity, there have been only a limited number of large clinical studies that safely assess its appropriate treatment and expected outcome. However, more safe data exist in terms of prognosis - which seems to be excellent, as almost all published studies regarding these tumours have confirmed so far. We present a systematic overview of breast EPC and of the most important studies published on this topic in order to make diagnosis and treatment more straightforward for cancer clinicians. The information for this review was compiled by searching the Pubmed, Medline, Scopus, Embase, and ISI Web of Science databases for articles published from 1980 through December 2012. Electronic early-release publications were also included.
    MeSH term(s) Carcinoma, Ductal, Breast/classification ; Carcinoma, Ductal, Breast/diagnosis ; Carcinoma, Ductal, Breast/diagnostic imaging ; Carcinoma, Ductal, Breast/surgery ; Carcinoma, Intraductal, Noninfiltrating/diagnosis ; Carcinoma, Papillary/classification ; Carcinoma, Papillary/diagnosis ; Epithelial Cells/pathology ; Female ; Humans ; Mammary Glands, Human/pathology ; Prognosis ; Ultrasonography
    Language English
    Publishing date 2013-10
    Publishing country India
    Document type Journal Article ; Review
    ZDB-ID 2187633-2
    ISSN 1998-4138 ; 0973-1482
    ISSN (online) 1998-4138
    ISSN 0973-1482
    DOI 10.4103/0973-1482.126448
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Malignant Myoepithelioma of the Parotid Gland

    Vassilios Kouloulias / John Tzitzikas / Μaria-Aggeliki Kalogeridi / George Kyrgias

    International Journal of Clinical Medicine, Vol 03, Iss 01, Pp 49-

    Literature Review on the Occasion of Our Report of a Case

    2012  Volume 54

    Abstract: Malignant myoepitheliomas are rare malignant salivary gland neoplasms which usually occur in the parotid gland. Very little material on this topic has been published. This tumour represents a therapeutic challenge since there are no specific ... ...

    Abstract Malignant myoepitheliomas are rare malignant salivary gland neoplasms which usually occur in the parotid gland. Very little material on this topic has been published. This tumour represents a therapeutic challenge since there are no specific recommendations or guidelines. We present a case of malignant myoepithelioma arising de novo in the parotid gland. We discuss our therapeutic approach and considerations on appropriate post-surgical treatment. Then we provide a review of international literature on this interesting and rare oncological entity.
    Keywords Malignant Myoepithelioma; Parotid ; Radiotherapy; Rare Neoplasms; Review ; Medicine (General) ; R5-920 ; Medicine ; R ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2012-01-01T00:00:00Z
    Publisher Scientific Research Publishing
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Brachytherapy for Prostate Cancer

    Vassilios Kouloulias / Vassilios Armonis / Nikolaos Kelekis / Georgios Koukourakis

    Advances in Urology, Vol

    A Systematic Review

    2009  Volume 2009

    Keywords Diseases of the genitourinary system. Urology ; RC870-923 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Urology ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2009-01-01T00:00:00Z
    Publisher Hindawi Publishing Corporation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article: Quality of Life and Psychological Distress of Caregivers' of Stroke People.

    Efi, Parpa / Fani, Katri / Eleni, Tsilika / Stylianos, Katsaragakis / Vassilios, Kouloulias / Konstantinos, Baliotis / Chrysoula, Lemonidou / Kyriaki, Mystakidou

    Acta neurologica Taiwanica

    2018  Volume 26, Issue 4, Page(s) 154–166

    Abstract: Purpose: Caregivers play a substantial role on support at stroke survivors after acute hospitalization. The aims of the current study were: to determine the quality of life of caregivers of patients with stroke, and to evaluate the predictors of quality ...

    Abstract Purpose: Caregivers play a substantial role on support at stroke survivors after acute hospitalization. The aims of the current study were: to determine the quality of life of caregivers of patients with stroke, and to evaluate the predictors of quality of life in caregivers.
    Methods: It is a cross-sectional study including 150 caregivers of patients with haemorrhagic or ischemic stroke. Participants completed the Greek version of the 12-item Short Form Health Survey assessing caregivers' quality of life. Caregiver burden was measured with the Revised Greek Bakas Caregiving Outcomes Scale, and psychological distress was screened with Greek Hospital Anxiety and Depression Scales.
    Results: A highly negative correlation was found between anxiety (r=0.56) and depression (r=0.59) with physical and mental health (r=0.44, 0.66, r=respectively) from quality of life subscales Physical Component Summary and Mental Component Summary scales. Physical health was influenced by caregivers' health problems (p less than 0.0005), type of stroke (p=0.014), anxiety (p=0.056), depression (p=0.024). Mental health was influenced by caregivers' health problems (p=0.051), burden, anxiety and depression (p less than 0.0005, respectively).
    Conclusions: Caregivers of people with stroke experience mental disorders and burden negatively affecting their quality of life. Therefore, there is a need to implement strategies which should aim to the management of these problems for the welfare of both patients and their caregivers.
    MeSH term(s) Caregivers ; Cross-Sectional Studies ; Depression ; Humans ; Quality of Life ; Stress, Psychological ; Stroke ; Surveys and Questionnaires
    Language English
    Publishing date 2018-10-12
    Publishing country China (Republic : 1949- )
    Document type Journal Article
    ZDB-ID 2192417-X
    ISSN 1028-768X ; 1019-6099
    ISSN 1028-768X ; 1019-6099
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Capecitabine for locally advanced and metastatic colorectal cancer

    Georgios V Koukourakis / Georgios Zacharias / John Tsalafoutas / Dimitrios Theodoridis / Vassilios Kouloulias

    World Journal of Gastrointestinal Oncology, Vol 2, Iss 8, Pp 311-

    A review

    2010  Volume 321

    Abstract: Capecitabine (Xeloda®) is an oral fluoropyrimidine which is produced as a pro-drug of fluorouracil, and shows improved tolerability and intratumor drug concentrations following its tumor-specific conversion to the active drug. We have searched the Pubmed ...

    Abstract Capecitabine (Xeloda®) is an oral fluoropyrimidine which is produced as a pro-drug of fluorouracil, and shows improved tolerability and intratumor drug concentrations following its tumor-specific conversion to the active drug. We have searched the Pubmed and Cochrane databases from 1980 to 2009 with the purpose of reviewing all available information on Capecitabine, focusing on its clinical effectiveness against colorectal cancer. Special attention has been paid to trials that compared Capecitabine with standard folinic acid (leucovorin, LV)-modulated intravenous 5-fluorouracil (5-FU) bolus regimens in patients with metastatic colorectal cancer. Moreover the efficacy of Capecitabine on metastatic colorectal cancer, either alone or in various combinations with other active drugs such as Irinotecan and Oxaliplatin was also assessed. Finally, neoadjuvant therapy consisting of Capecitabine plus radiation therapy, for locally advanced rectal cancer was analysed. This combination of chemotherapy and radiotherapy has a special role in tumor down staging and in sphincter preservation for lower rectal tumors. Comparative trials have shown that Capecitabine is at least equivalent to the standard LV-5-FU combination in relation to progression-free and overall survival whilst showing a better tolerability profile with a much lower incidence of stomatitis. It is now known that Capecitabine can be combined with other active drugs such as Irinotecan and Oxaliplatin. The combination of Oxaliplatin with Capecitabine represents a new standard of care for metastatic colorectal cancer. Combinating the Capecitabine-Oxaliplatin regimen with promising new biological drugs such as Bevacizumab seems to give a realistic prospect of further improvement in time to progression of metastatic disease. Moreover, preoperative chemo-radiation using oral capecitabine is better tolerated than bolus 5-FU and is more effective in the promotion of both down-staging and sphincter preservation in patients with locally advanced rectal cancer. Finally, the outcomes of recently published trials suggest that capecitabine seems to be more cost effective than other standard treatments for the management of patients with colorectal cancer.
    Keywords Chemo-radiotherapy ; Colorectal cancer ; Capecitabine ; Oxaliplatin ; Xeloda ; Diseases of the digestive system. Gastroenterology ; RC799-869 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Gastroenterology ; DOAJ:Medicine (General) ; DOAJ:Health Sciences ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282 ; DOAJ:Oncology
    Subject code 610
    Language English
    Publishing date 2010-08-01T00:00:00Z
    Publisher Baishideng Publishing
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Comprehensive Management of Upper Tract Urothelial Carcinoma

    Georgios Koukourakis / Georgios Zacharias / Michael Koukourakis / Kiriaki Pistevou-Gobaki / Christos Papaloukas / Athanasios Kostakopoulos / Vassilios Kouloulias

    Advances in Urology, Vol

    2009  Volume 2009

    Keywords Diseases of the genitourinary system. Urology ; RC870-923 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Urology ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2009-01-01T00:00:00Z
    Publisher Hindawi Publishing Corporation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Comprehensive Management of Upper Tract Urothelial Carcinoma

    Vassilios Kouloulias / Athanasios Kostakopoulos / Christos Papaloukas / Kiriaki Pistevou-Gobaki / Michael Koukourakis / Georgios Zacharias / Georgios Koukourakis

    Advances in Urology, Vol

    2008  Volume 2009

    Abstract: Urothelial carcinoma of the upper urinary tract represents only 5% of all urothelial cancers. The 5-year cancer-specific survival in the United States is roughly 75% with grade and stage being the most powerful predictors of survival. Nephroureterectomy ... ...

    Abstract Urothelial carcinoma of the upper urinary tract represents only 5% of all urothelial cancers. The 5-year cancer-specific survival in the United States is roughly 75% with grade and stage being the most powerful predictors of survival. Nephroureterectomy with excision of the ipsilateral ureteral orifice and bladder cuff en bloc remains the gold standard treatment of the upper urinary tract urothelial cancers, while endoscopic and laparoscopic approaches are rapidly evolving as reasonable alternatives of care depending on grade and stage of disease. Several controversies remain in their management, including a selection of endoscopic versus laparoscopic approaches, management strategies on the distal ureter, the role of lymphadenectomy, and the value of chemotherapy in upper tract disease. Aims of this paper are to critically review the management of such tumors, including endoscopic management, laparoscopic nephroureterectomy and management of the distal ureter, the role of lymphadenectomy, and the emerging role of chemotherapy in their treatment.
    Keywords Diseases of the genitourinary system. Urology ; RC870-923 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Urology ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2008-12-01T00:00:00Z
    Publisher Hindawi Publishing Corporation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment

    John Kouvaris / Haralabos Zabatis / Georgios A. Zacharias / Michael J. Koukourakis / Vassilios Kouloulias / Georgios V. Koukourakis

    Molecules, Vol 13, Iss 8, Pp 1897-

    a Review

    2008  Volume 1922

    Abstract: Abstract: Capecitabine (Xeloda®) was developed as a pro-drug of fluorouracil (FU), with the aim of improving tolerability and intratumor drug concentrations through its tumorspecific conversion to the active drug. The purpose of this paper is to ... ...

    Abstract Abstract: Capecitabine (Xeloda®) was developed as a pro-drug of fluorouracil (FU), with the aim of improving tolerability and intratumor drug concentrations through its tumorspecific conversion to the active drug. The purpose of this paper is to review the available information on capecitabine, focusing on its clinical effectiveness against various carcinomas. Identification of all eligible English trails was made by searching the PubMed and Cochrane databases from 1980 to 2007. Search terms included capecitabine, Xeloda and cancer treatment. Nowadays, FDA has approved the use of capecitabine as a first line therapy in patients with metastatic colorectal cancer when single-agent fluoropyrimidine is preferred. The drug is also approved for use as a single agent in metastatic breast cancer patients who are resistant to both anthracycline and paclitaxel-based regimens or when further anthracycline treatment is contraindicated. It is also approved in combination with docetaxel after failure of prior anthracycline-based chemotherapy. In patients with prostate, pancreatic, renal cell and ovarian carcinomas, capecitabine as a single-agent or in combination with other drugs has also shown benefits. Improved tolerability and comparable efficacy, compared with the intravenous FU/LV combination, in addition to its oral administration, make capecitabine an attractive option for the treatment of several types of carcinomas.
    Keywords Capecitabine ; Xeloda ; cancer treatment ; Organic chemistry ; QD241-441
    Subject code 610
    Language English
    Publishing date 2008-08-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Temozolomide with Radiation Therapy in High Grade Brain Gliomas

    Demetrios Chaldeopoulos / Ivelina Beli / Andreas Fotineas / George Maravelis / Panagiotis Pantelakos / Christos Papadimitriou / Georgios Zacharias / Vassilios Kouloulias / Georgios V. Koukourakis / John Kouvaris

    Molecules, Vol 14, Iss 4, Pp 1561-

    Pharmaceuticals Considerations and Efficacy;A Review Article

    2009  Volume 1577

    Abstract: Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) which have a combined incidence of 5–8/100,000 population, represent the most common primary central nervous system tumors. The treatment outcomes even with aggressive approach ... ...

    Abstract Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) which have a combined incidence of 5–8/100,000 population, represent the most common primary central nervous system tumors. The treatment outcomes even with aggressive approach including surgery, radiaton therapy and chemotherapy are dismal with median reported survival is less than 1 year. Temozolomide is a new drug which has shown promise in treating malignant gliomas and other difficult-to-treat tumors. This drug is a per os (p.o) imidazotetrazine second-generation alkylating agent which represents the leading compound in a new class of chemotherapeutic agents that enter the cerebrospinal fluid and do not require hepatic metabolism for activation. The efficacy of temozolomide was tested in vitrostudies and has demonstrated schedule-dependent antitumor activity against highly resistant malignancies, including high-grade glioma (HGG). In addition, in clinical studies, temozolomide consistently demonstrates reproducible linear pharmacokinetics with approximately 100% p.o. bioavailability, noncumulative minimal myelosuppression that is rapidly reversible, and activity against a variety of solid tumors in both children and adults. Moreover, preclinical studies have evaluated the combination of temozolomide with other alkylating agents and inhibitors of the DNA repair protein O6-alkylguanine alkyltransferase to overcome resistance to chemotherapy in malignant glioma and malignant metastatic melanoma. At the present time temozolomide is approved in the United States for the treatment of adult patients with refractory anaplastic astrocytoma and, in the European Union, for treatment of glioblastoma multiforme showing progression or recurrence after standard therapy. Temozolomide’s characteristics which make it a candidate for a wide range of clinical testing to evaluate the potential of combination treatments in different tumor types are its predictable bioavailability and minimal toxicity. An overview of the mechanism of action of temozolomide and ...
    Keywords Temozolomide ; Malignant gliomas ; Chemotherapy ; Radiation therapy ; Organic chemistry ; QD241-441
    Subject code 610
    Language English
    Publishing date 2009-04-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top